公开(公告)号：EP2234978A1

公开(公告)日：2010-10-06

申请号：EP08865783.8

申请日：2008-12-18

申请人： AstraZeneca AB

发明人： BAUER, Udo, Andreas ,  BIRCH, Alan, Martin ,  BUTLIN, Roger, John ,  GREEN, Clive ,  BARLIND, Jonas, Gunnar ,  HOVLAND, Ragnar ,  JOHANNESSON, Petra ,  JOHANSSON, Jan, Magnus ,  LEACH, Andrew ,  NOESKE, Alexander, Tobias ,  PETERSSON, Annika, Ulrika

IPC分类号： C07D213/81 ,  C07D213/82 ,  C07D241/24 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  A61K31/4418 ,  A61K31/4965 ,  A61K31/497 ,  A61P3/00

CPC分类号： C07D213/81 ,  C07D213/82 ,  C07D241/24 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10

摘要： DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

公开(公告)号：EP2234978B1

公开(公告)日：2015-02-25

申请号：EP08865783.8

申请日：2008-12-18

申请人： AstraZeneca AB

发明人： BAUER, Udo, Andreas ,  BIRCH, Alan, Martin ,  BUTLIN, Roger, John ,  GREEN, Clive ,  BARLIND, Jonas, Gunnar ,  HOVLAND, Ragnar ,  JOHANNESSON, Petra ,  JOHANSSON, Jan, Magnus ,  LEACH, Andrew ,  NOESKE, Alexander, Tobias ,  PETERSSON, Annika, Ulrika

IPC分类号： C07D213/81 ,  C07D213/82 ,  C07D241/24 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  A61K31/4418 ,  A61K31/4965 ,  A61K31/497 ,  A61P3/00

CPC分类号： C07D213/81 ,  C07D213/82 ,  C07D241/24 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10